Research library / Longevity compounds
BB Good human data, but mixed outcomes or surrogate markers. How we grade →RCT · 1,429 people with impaired glucose tolerance
Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance
J Chiasson, R Josse, R Gomis, M Hanefeld, A Karasik, M Laakso et al. JAMA. 2003.
- In plain language
- STOP-NIDDM: acarbose 100 mg three times a day was linked to fewer cardiovascular events (HR 0.51) and less new hypertension over about 3.3 years.
- Limits
- 24% stopped early, more on acarbose (211 vs 130). The larger ACE trial did not confirm a cardiovascular benefit.
- Which of our grades it feeds
- DD Mostly mechanistic or early data. Shown openly. How we grade →Science summary: Notes on the Blueprint protocol
- Source
- doi.org/10.1001/jama.290.4.486 · PubMed 12876091
Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. We sell some of what we grade.